Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“Because Multiple Myeloma is primarily a disease of the elderly, it is incumbent on geriatricians and primary care providers to understand the best course of management for their patients with this disease…”
Multiple Myeloma is an incurable but very treatable cancer. This is a confusing statement that means that there is a long and growing list of both conventional FDA approved therapies and evidence-based non-conventional MM therapies. And older adults facing a Multiple Myeloma diagnosis may think about quality of life more than quantity of life when considering toxic therapies such as chemotherapy and radiation.
I am a long-term MM survivor and MM cancer coach. I have remained in complete remission from my MM since 1999 by living an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation, bone health and more.
To learn more about evidence-based, non-conventionl, non-toxic therapies, managing and alleviating side effects, and overall structuring your life to support your body and fight Multiple Myeloma, please watch the video below:
“Multiple myeloma (MM) is a progressive and fatal disease, primarily affecting men aged 66 years or older. Because MM is primarily a disease of the elderly, it is incumbent on geriatricians and primary care providers to understand the best course of management for their patients with this disease. Although the acute management of MM is driven by specialists, the identification of MM and management outside of the oncologist’s office will fall to geriatric care providers…
Initial diagnostic testing must be ordered upon clinical suspicion of MM. These tests include complete blood count (CBC) with peripheral blood smear; serum calcium; basic metabolic panel, to evaluate creatinine; liver function test, to evaluate albumin; lactate dehydrogenase test (LDH); beta-2 microglobulin; and C-reactive protein, to determine prognosis of the disorder. At the same time, serum protein electrophoresis and immunofixation, serum free light chain assay, and a 24-hour urine protein for electrophoresis and immunofixation should be performed.19-22 Beta-2 microglobulin levels, along with albumin, are used for staging and prognosis of MM...
“Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15% of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older…
Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM.
Decision making about which therapies and their dose intensity and duration should be influenced by a patient’s functional status, personal preferences, disease characteristics, and ability to tolerate therapy.
The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival.
Again, consideration of quality of life for these patients is paramount.
Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.
KEY POINTS
Overall survival for elderly patients with MM is gradually improving, but at a slower rate than for younger patients.
Assessment of frailty and geriatric assessments should play a role in treatment decisions.
ASCT is a viable treatment option for nonfrail patients.
Targeting minimal residual disease may be appropriate for the elderly patient population with MM, but the optimal balance between longevity and quality of life has not yet been established.
Further clinical trials will be required to optimize decision making for this complex patient population…”
